中药的抗肿瘤作用.doc

1 (1) 1 S180TNKIL-2CTL12NKT2 AK56234HepG2HepG2HepG2G1/G0SSG2/MSDNADNASPGPGc AMP/c GMPPG5!-empirenews.page-3 SG2HL-602DNAHL-6024650g/mlKB7241.9%KBG0/G17PML-RARBcl-28HL-60U93794 DNADNA10DNAG2S11DMSO2.3g/ml80g/mlPbr322DNA12DNADNABufalinBufalinS131415DNA5 16176 12107181962TNFTNF20!-empirenews.page-123 IFN21TNFINFLee22Bufalin5 nmol/LBufalinFCMG2/M2310g/ml0.1mg/mlEp7 rasp21rasGGTPrasp53p53p53p53p5325p21rasp53rasp53bcl-2baxbcl-2bax266T-CEMbcl-2bcl-2/bax6T-CEM2729c-mycc-fosRb8 multidrug resistance ,MDRMDRP-P-gp30MTTKBv200KBKBv200K562/ADRK562/VCRMDR1mRNA,P-gp31BEL-7402BEL-7402/DOXBEL-7402P-gp32!-empirenews.page-9 3310%50%34353610 1199627211622002102223A20003122074200027318852000239554619961831697200076258 Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (AS2O3) in the treatment of acute prom yeolcytic leukemia: AS2O3 induces NB4 cell apoptosm with down-regulation of bcl-2 expression and modulation of PMLRARd/PML proteins. 1996; 88(3): 10529199919337102000315011 Liu LF, Desai SD, Li TK, et al. Mechnism of action of camptothecin. Ann-N-Acad-Sci. 2000; 92: 2112DNADNA200019866113Bafalin200027420114DNAK5621999186661!-empirenews.page-15HL-60DNA199920654116 Kaye SB. Progress in the treatment of ovarian Cancer. Anti Cancer Druges. 1999; 9: 27311720012345218 Folkman J. Clinical applications of research on angiogenesis. N Eng/J Med 1995; 333: 177519200011417520199231721123 199413422 Lee DY, Yasuda M, Yamamoto T, et al. Bufalin inhibits endothelial cell proliferation and angiogenesis in vitro. Life Sci. 1997;60(2):127 23200020431324, , , 20041212725p21rasp532001211073626T200041317627K562 200221437028H22Ca+Ca+/Mg+-ATPc-fos20004422